Related Experiment Videos
Pharmacogenetics, race and global injustice
1Cardiff Law School, Cardiff University, Museum Avenue, Cardiff CF10 3XJ, United Kingdom. holms@cardiff.ac.uk
Developing World Bioethics
|January 15, 2009
Summary
Pharmacogenetics research shows race is not a reliable proxy for genetic traits. This has significant global justice implications, especially for healthcare in low- and middle-income countries.
Area of Science:
- Pharmacogenetics
- Global Health Equity
- Bioethics
Background:
- Pharmacogenetics, the study of genetic variations influencing drug response, is rapidly advancing.
- The integration of pharmacogenetics into medicine raises complex ethical and social questions.
- Existing healthcare disparities may be exacerbated by the introduction of pharmacogenetics.
Purpose of the Study:
- To examine the relationship between pharmacogenetic traits and the social construct of race.
- To analyze the global justice issues arising from pharmacogenetics in pharmaceutical research and clinical practice.
- To assess the impact of pharmacogenetics on healthcare systems in resource-limited settings.
Main Methods:
- Literature review of pharmacogenetics and race.
- Analysis of ethical and social implications.
- Examination of global health policy and disparities.
Main Results:
- A problematic and scientifically unsupported link exists between perceived race and pharmacogenetic profiles.
- Race is an inadequate proxy for predicting pharmacogenetic variations.
- Significant challenges and ethical considerations arise for implementing pharmacogenetics in low- and middle-income countries.
Conclusions:
- Race should not be used as a surrogate for pharmacogenetic information in research or clinical settings.
- The development of pharmacogenetics necessitates careful consideration of global justice and equitable access.
- Policy frameworks must address potential disparities to ensure fair implementation of pharmacogenetics worldwide.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...